Table 3. Baseline characteristics for the COPACETIC cohort according to rs1051730 and rs8034191 genotypes.
| rs1051730 | rs8034191 | |||||||
| AA(n = 134) | GA(n = 562) | GG(n = 530) | p-value | GG(n = 133) | GA(n = 560) | AA(n = 531) | p-value | |
| Demographics | ||||||||
| Age, mean (SD), yr | 59.6 (6.0) | 59.6 (5.3) | 59.7 (5.4) | 0.952 | 59.6 (5.7) | 59.6 (5.2) | 59.8 (5.4.) | 0.739 |
| Pack year history, mean (SD), yr | 39.3 (15.9) | 41.4 (17.4) | 40.2 (17.7) | 0.301 | 39.7 (17.4) | 41.6 (17.6) | 39.9 (17.2) | 0.209 |
| Current smokers, no (%) | 76 (56.7%) | 333 (59.3%) | 344 (64.9%) | 0.093 | 75 (56.4%) | 341 (60.9%) | 337 (63.5%) | 0.298 |
| Years quit smoking % (no) | 0.307 | 0.356 | ||||||
| 0 | 57.8% (78) | 59.4% (337) | 64.8% (346) | 57.0% (75) | 60.9% (344) | 63.4% (339) | ||
| <1 | 7.4% (10) | 6.4% (35) | 7.8% (41) | 6.7% (9) | 6.5% (35) | 7.9 5 (42) | ||
| 1–5 | 18.5% (24) | 18.5% (102) | 14.3% (74) | 19.3% (25) | 17.5% (97) | 15.2% (79) | ||
| >5 | 16.3% (22) | 15.7% (88) | 13.1% (69) | 17.0% (23) | 15.2% (84) | 13.5% (71) | ||
| Age started smoking % (no) | 0.491 | 0.397 | ||||||
| <14 years | 14.9% (20) | 19.2% (118) | 17.4% (92) | 16.5% (22) | 18.8% (111) | 16% (87) | ||
| 15–19 years | 70.2% (94) | 65.8% (395) | 67.7% (359) | 67.0% (91) | 65.7% (378) | 68.4% (368) | ||
| >20 | 14.9% (20) | 15.0% (48) | 14.9% (79) | 16.5% (22) | 11.8% (71) | 13.7% (76) | ||
| Pulmonary function tests, mean (SD) | ||||||||
| FEV1, L | 3.26 (0.76) | 3.29 (0.73) | 3.41 (0.72) | 0.013 | 3.24 (0.74) | 3.29 (0.74) | 3.41 (0.71) | 0.008 |
| FEV1, % predicted | 94.4 (19.5) | 95.1 (18.5) | 98.6 (17.9) | 0.003 | 94.1 (18.8) | 95.2 (19.0) | 98.6 (17.4) | 0.002 |
| FEV1/FVC ratio | 0.70 (0.10) | 0.71 (0.10) | 0.72 (0.107) | 0.002 | 0.71 (0.10) | 0.70 (0.11) | 0.72 (0.10) | 0.002 |
| MEF50, L/s | 2.97 (1.44) | 2.95 (1.39) | 3.25 (1.50) | 0.002 | 2.94 (1.38) | 2.96 (1.44) | 3.24 (1.47) | 0.003 |
| COPD severity, no. (%) | 0.004 | 0.010 | ||||||
| No Obstruction | 67 (50%) | 291 (51.6%) | 326 (61.3%) | 71 (52.2%) | 286 (51.2%) | 326 (61.2%) | ||
| GOLD class I | 38 (28.4%) | 181 (32.2%) | 138 (26.0%) | 39 (28.4%) | 176 (31.4%) | 143 (26.9%) | ||
| GOLD class II | 27 (20.1) | 74 73 (13.2%) | 61 (11.5%) | 24 (17.9%) | 81 (14.4%) | 57 (10.7%) | ||
| GOLD class III | 2 (1.5%) | 17 17 (3.0%) | 5 (0.9%) | 2 (1.5%) | 17 (3.0%) | 5 (0.9%) | ||
FEV1: forced expiratory volume in one second; FVC: forced vital capacity; MEF50 maximum expiratory flow when 50% of the FVC has been exhaled; GOLD: global initiative for chronic obstructive lung disease. Percentages are column percentages. Genotyping succeeded in 1226 (100%) and 1224 (99.8%) COPACETIC participants, respectively for rs1051730 and rs8034191.